PCSK9 and acne: This MR study offered preliminary evidence of a beneficial association between drugs such as alirocumab (proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors), LDLR, and LPL inhibitors, and a reduced risk of acne vulgaris.